CA-ADTRAN
7.3.2023 14:01:41 CET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of open and disaggregated networking solutions, today announced that its latest coherent innovation will be showcased at OFC as part of OFCnet. The demo reveals how the Adtran FSP 3000 open line system (OLS) can bring new levels of flexibility to optical networks by enabling optimized, tailored spectrum services. In collaboration with Acacia, Cisco, Coherent Corp., Corning, EXFO, Nokia and VIAVI Solutions, Adtran will showcase 100ZR, 200Gbit/s, 400Gbit/s OpenZR+ and 800Gbit/s connectivity. The FSP 3000 DCI OLS is also playing a key role in the OIF 400ZR demo at OFC.
“Our demo shows how the spectrum-as-a-service concept has the potential to revolutionize the way operators utilize their fiber resources. It highlights how it’s possible to slice up the network even in a metro environment. With fully flexible spectrum allocation, operators can provide a wide variety of differentiated services and ensure they leverage the full capacity of their infrastructure. Not only will this help tackle ever-increasing data demand, but it also offers a new route to revenue growth,” said Jörg-Peter Elbers, head of advanced technology at Adtran. “Our compact FSP 3000 OLS is the key to realizing the full benefits of this open and flexible approach. It removes the limits of fixed channel grids so that untapped spectrum can be put to work.”
The coherent innovation demo features a three-node ring network with flexgrid ROADMs in the Adtran, Coherent Corp. and OFCnet booths. Adtran’s FSP 3000 OLS is used to ensure strict separation between users while minimizing the unused bandwidth between their spectrum services, and its high-resolution flexgrid ROADMs provide optical channel monitoring, demarcation and passband optimization for all spectrum services. Also on display is the Adtran TeraFlex™ CoreChannel™, which transports 100Gbit/s and 400Gbit/s Ethernet client signals over a coherent 800Gbit/s signal. In combination with Adtran’s MicroMux™, the terminal shows the transmission of 10Gbit/s services without any footprint increase. What’s more, Adtran’s OpenFabric+™ is being used to demonstrate 200Gbit/s connectivity.
“One of the most exciting elements of this demo is showcasing the value of our Coherent 100ZR. To meet growing traffic demands, network operators need to upgrade their edge aggregation infrastructure to support 100Gbit/s rates. However, this can be a costly and complex process. With its QSFP28 form factor, our Coherent 100ZR easily fits into existing host platforms and can operate over any optical network infrastructure. This facilitates the adoption of 100Gbit/s coherent technology at the network edge without major infrastructure changes and at an affordable price,” commented Ross Saunders, GM of Optical Engines, Adtran. “With a new purpose-built DSP, a standards-compliant QSFP28 form factor, and 5W power consumption, our Coherent 100ZR opens the door to widespread rollout of 100Gbit/s coherent technology at the optical edge.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
